Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals develops therapies for diseases caused by uncontrolled gene expression.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Ionis Pharmaceuticals’ stock, anticipating it will rise above its current price.
Financial Health
Ionis Pharmaceuticals is achieving strong revenue and cash flow, with impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IONS
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketTargeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketBio-Hacking Portfolio
Discover companies at the cutting edge of human optimization, where biology meets technology. These carefully selected stocks represent innovators developing data-driven solutions for personalized health, enhanced performance, and extended longevity.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Antisense Platform
A platform approach can create multiple development candidates from one technology, which investors may find compelling though outcomes vary and timelines are long.
Partner Deals Matter
Collaborations with larger pharma provide funding and commercial reach, but revenues often depend on milestone timing and partner strategy.
Clinical Catalysts Ahead
Upcoming trial readouts and regulatory decisions can significantly move the share price, but those events also carry binary downside risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
